The stock of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) is a huge mover today! About 822,488 shares traded hands or 29.04% up from the average. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has risen 90.34% since April 8, 2016 and is uptrending. It has outperformed by 84.69% the S&P500.
The move comes after 9 months positive chart setup for the $787.30M company. It was reported on Nov, 10 by Barchart.com. We have $22.74 PT which if reached, will make NASDAQ:VNDA worth $291.30M more.
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Ratings Coverage
Out of 5 analysts covering Vanda Pharmaceuticals (NASDAQ:VNDA), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Vanda Pharmaceuticals has been the topic of 7 analyst reports since September 2, 2015 according to StockzIntelligence Inc. As per Friday, August 26, the company rating was maintained by JMP Securities. The firm earned “Buy” rating on Wednesday, October 21 by Brean Capital. The stock has “Buy” rating given by Jefferies on Thursday, October 6. The stock of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) earned “Buy” rating by Piper Jaffray on Wednesday, September 2. The rating was initiated by Aegis Capital with “Buy” on Wednesday, November 9. The stock of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has “Market Outperform” rating given on Wednesday, March 9 by JMP Securities.
According to Zacks Investment Research, “Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It’s lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It’s second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It’s third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial.”
Insitutional Activity: The institutional sentiment increased to 1.02 in 2016 Q2. Its up 0.10, from 0.92 in 2016Q1. The ratio is positive, as 19 funds sold all Vanda Pharmaceuticals Inc. shares owned while 33 reduced positions. 19 funds bought stakes while 34 increased positions. They now own 36.20 million shares or 6.54% less from 38.73 million shares in 2016Q1.
The New Jersey-based Princeton Alpha L P has invested 0.04% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Allianz Asset Mngmt Ag last reported 48,140 shares in the company. Moreover, Invesco has 0% invested in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) for 12,277 shares. Tudor Corp Et Al owns 12,719 shares or 0% of their US portfolio. Vanguard Gru has 1.61 million shares for 0% of their US portfolio. Tiaa Cref Invest Mgmt Lc accumulated 0% or 298,773 shares. Springbok Cap Mgmt Limited Com accumulated 0.01% or 3,346 shares. Amici Cap Ltd Liability Corporation last reported 0.11% of its portfolio in the stock. Metropolitan Life Insurance Ny last reported 0% of its portfolio in the stock. Amer Grp Inc reported 21,095 shares or 0% of all its holdings. Deerfield Mgmt holds 2.64% or 6.00M shares in its portfolio. Blackrock Japan last reported 1,755 shares in the company. Kingdon Management Lc accumulated 0.4% or 644,568 shares. Susquehanna Llp holds 0% or 117,513 shares in its portfolio. Ubs Asset Mgmt Americas Inc last reported 0% of its portfolio in the stock.
Insider Transactions: Since September 15, 2016, the stock had 0 insider buys, and 2 sales for $27.14 million net activity. $18.56M worth of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) was sold by Flynn James E on Thursday, September 22.
More notable recent Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) news were published by: Prnewswire.com which released: “Vanda Pharmaceuticals Reports Third Quarter 2016 Financial Results” on November 02, 2016, also Prnewswire.com with their article: “Vanda Pharmaceuticals Settles Fanapt® Patent Litigation with Taro” published on October 24, 2016, Prnewswire.com published: “Vanda Pharmaceuticals Reports Second Quarter 2016 Financial Results” on July 27, 2016. More interesting news about Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) were released by: Prnewswire.com and their article: “Vanda Pharmaceuticals to Announce Third Quarter 2016 Financial Results on …” published on October 12, 2016 as well as Prnewswire.com‘s news article titled: “Vanda Pharmaceuticals Reports First Quarter 2016 Financial Results” with publication date: May 04, 2016.
VNDA Company Profile
Vanda Pharmaceuticals Inc., incorporated on November 13, 2002, is a biopharmaceutical company. The Firm is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company’s product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.